Trump gave patients a 'right to try.' It hasn't helped them

MediaBiasFactChecker Bot , 9 hours ago

STAT (News) Media Bias Fact Check Credibility: [High] (Click to view Full Report)> Name: statnews.com> Bias: Left-Center
> Factual Reporting: High
> Country: United States of America
> Full Report: mediabiasfactcheck.com/stat-news/
Check the bias and credibility of this article on Ground.News

---

Thanks to Media Bias Fact Check for their access to the API.
Please consider supporting them by donating.

FooterBeep boop. This action was performed automatically. If you dont like me then please block me.💔
If you have any questions or comments about me, you can make a post to LW Support lemmy community.

SuckMyWang , 8 hours ago

I thought this was a good thing trump did

jeffw OP , 8 hours ago

It wasn’t bad, just wasn’t really much

adarza , 7 hours ago

it was nothing–it was worse than nothing.

it was a sham to remove oversight and accountability from something that already existed. slap the trump name on it, maybe collect some ‘contributions’ from the few companies or their investors that profited.

Snapz , 7 hours ago

Space force!

memfree , 7 hours ago

We already had the Expanded Access Program (thank you ACT UP) and we don’t want a repeat of thalidomide babies like we had before there were strong protections on how drugs get tested.

So now we have Expanded Access (EAP) with FDA oversite and Right to Try (RTT) without that oversight. Having both is confusing for everyone and most people don’t know which covers what. From Journal of Law and the Biosciences (they only sampled 17 neuro-oncologists from 15 different academic medical centers):

Many physicians described having difficulty in distinguishing between RTT and EAP or demonstrated misconceptions in their responses. A physician with knowledge of both pathways spoke about his colleagues generally: ‘I don’t think a lot of people understand the difference between expanded access and Right-To-Try’ [Participant 1]. The confusion resulted in conflation with the different features between EAP and RTT including structure, intent, and processes of these pathways. In response to our question ‘Have you provided a drug through Right-to-Try?’ one clinician erroneously replied, ‘I think most compassionate use is under that category’ [Participant 2]. Another drew a rough equivalence between the two despite the absence of FDA oversight for RTT: ‘I guess the way I try to think about Right-to-Try is like compassionate use.